ART-AD Study

A new approach to dementia treatment- targeting the proteins connected to memory loss.

Study at a Glance

Estimated Time Commitment

8 visits over 6-7 months


Ages 50 to 80 years

Diagnosis Required

Alzheimer's disease

Diseases Being Studied

Alzheimer's disease


Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B.
Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.
Over the course of this trial, we will measure the success of the drug in preventing further neurodegeneration.


Qualifications to participate include, but are not limited to:

  • Adults ages 50-80 years
  • Clinical diagnosis of early Alzheimer’s disease
  • Have a reliable informant or caregiver

If participants are taking Alzheimer’s medications, they must be on a stable dose for at least 8 weeks before first screening visit.


Disqualifications to participate include, but are not limited to:

    • Patients taking memantine medication


Treatment will include 8 study visits over 6-7 months.
The 6-7 months will include 30 days of pre-treatment, a 24-week treatment period and a follow up visit one month following treatment.

Pre-treatment visits include:

      • Comprehensive neuropsychological exams
      • Tablet-based neuropsychological exams
      • Lumbar puncture to collect cerebrospinal fluid
      • Blood draw

During treatment, visits include:

      • Review of medication
      • Physical examinations
      • Brief cognitive screenings
      • Blood draw

The post-treatment visit one month after the final dose of medication includes a:

    • Comprehensive neuropsychological exam
    • Lumbar puncture to collect cerebrospinal fluid
    • Blood draw
    • Disenrollment

Meet Your Clinical Research Team

Contact us

Barshop Institute for Aging and Longevity